

# Vaccines and Global Health: The Week in Review 02 November 2024 :: Issue 773 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks

## Milestones, Perspectives

::::::

TB

#### Global tuberculosis report 2024

October 2024 :: 68 pages

PDF: <a href="https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1">https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1</a>
<a href="https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1">https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1</a>
<a href="https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1">https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1</a>
<a href="https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1">https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1</a>

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2024 edition of the report is, as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2024, 193 countries and areas with more than 99% of the world's population and TB cases reported data.

The core report document focuses on the main findings and messages. This is accompanied by webpages that provide more detailed and digitized content, including many interactive graphics; and an app containing country, regional and global profiles...

## **Main findings and messages** [excerpt]

Ending the global TB epidemic remains a distant goal but there are several positive trends following strong post-COVID recovery efforts that continued in 2023. These include:

- :: the global rise in the number of people falling ill with TB each year has slowed and started to stabilize;
- :: the global number of people dying from TB each year continues to fall;
- :: the WHO African and European regions have made good progress towards the 2025 milestones for reductions in the TB incidence rate and the number of deaths caused by TB;
- :: the globally reported number of people newly diagnosed with TB reached a new high in 2023;
- :: the treatment success rate for people with drug-susceptible TB has been sustained at a high level and continues to improve for people with drug-resistant TB;
- :: the coverage of TB preventive treatment has been sustained for people living with HIV and continues to improve for household contacts of people diagnosed with TB.


At the same time, global milestones and targets for reductions in TB disease burden are off-track and other targets set for 2027 at the second UN high-level meeting remain some way off. Wider progress towards UHC and higher levels of social protection, action on TB determinants (e.g. poverty, undernutrition and HIV) and TB research and innovation remain essential.

Accelerating progress towards ending TB requires that commitments made at the second UN high-level meeting on TB in 2023 are translated into action...


Tuberculosis is as old as humanity itself. It has afflicted kings and queens, poets and politicians, revolutionaries and writers, activists and actors. Most of its victims, however, are poor, marginalised or malnourished, and the out-of-pocket costs associated with treating TB expose them to financial hardship or drive them further into poverty. TB is the definitive disease of deprivation. Turning the tide on TB means screening and treatment for those it strikes, and preventing it by addressing its drivers and developing a new vaccine. Only by working together can we turn the tide against this ancient killer. Dr. Tedros Adhanom Ghebreyesus, Director-General, World Health Organization

## Global TB milestones and targets: latest status of progress

## End TB Strategy, 2025 milestones



## 2023 UN high-level meeting on TB, targets<sup>c</sup>



#### TPT, TB preventive treatment.

- a This is the end of 2023 for all indicators unless otherwise stated.
- b This indicator is not the same as the SDG indicator for catastrophic health expenditures. See Box 3 for further explanation.
- There is also a target that all people with TB have access to a health and social benefits package by 2027. Methods to assess progress towards this target are in development.
- The length of the arrow represents 1 year (out of five) since the 2023 UN-high level meeting on TB.

#### Tuberculosis resurges as top infectious disease killer

29 October 2024 News release

The World Health Organization (WHO) today published a **new report on tuberculosis revealing** that approximately 8.2 million people were newly diagnosed with TB in 2023 – the highest number recorded since WHO began global TB monitoring in 1995. This represents a notable increase from 7.5 million reported in 2022, placing TB again as the leading infectious disease killer in 2023, surpassing COVID-19.

WHO's <u>Global Tuberculosis Report 2024</u> highlights mixed progress in the global fight against TB, with persistent challenges such as significant underfunding. While the number of TB-related deaths decreased from 1.32 million in 2022 to 1.25 million in 2023, the total number of people falling ill with TB rose slightly to an estimated 10.8 million in 2023.

With **the disease disproportionately affecting people in 30 high-burden countries,** India (26%), Indonesia (10%), China (6.8%), the Philippines (6.8%) and Pakistan (6.3%) together accounted for 56% of the global TB burden. According to the report, 55% of people who developed TB were men, 33% were women and 12% were children and young adolescents.

"The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "WHO urges all countries to make good on the concrete commitments they have made to expand the use of those tools, and to end TB."

In 2023, the gap between the estimated number of new TB cases and those reported narrowed to about 2.7 million, down from COVID-19 pandemic levels of around 4 million in 2020 and 2021. This follows substantial national and global efforts to recover from COVID-related disruptions to TB services. The coverage of TB preventive treatment has been sustained for people living with HIV and continues to improve for household contacts of people diagnosed with TB.

**However, multidrug-resistant TB remains a public health crisis.** Treatment success rates for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) have now reached 68%. But, of the 400 000 people estimated to have developed MDR/RR-TB, only 44% were diagnosed and treated in 2023...

::::::

#### Polio - PHEIC

[No GPEI weekly update identified]

Gaza: Strike hits health centre as polio vaccine campaign resumes in ravaged north 2 November 2024

The long-awaited final phase of a UN-supported polio vaccine campaign began on Saturday in bombarded, besieged northern Gaza even as **reports emerged that one vaccination centre had been hit during a humanitarian pause**, **according to UN agencies on the ground**.

Hours after the campaign rolled out, reports indicated that a healthcare centre in the north had been hit, injuring six people, including four children, in a location where a humanitarian pause had been in place, according to the World Health Organization (WHO) chief.

"We have received an extremely concerning report that the Sheikh Radwan primary healthcare centre in northern Gaza was struck today while parents were bringing their children to the lifesaving polio vaccination in an area where a humanitarian pause was agreed to allow vaccination to proceed, " said Tedros Adhanom Ghebreyesus in a social media <u>post</u>. He said a WHO team was at the site just before.

"This attack, during humanitarian pause, jeopardises the sanctity of health protection for children and may deter parents from bringing their children for vaccination," he said. "These vital humanitarian-area-specific pauses must be absolutely respected."

## Campaign unrolls despite challenges

"To overcome challenges posed by the volatile security situation and constant population movement, robust micro plans have been developed to ensure the campaign is responsive to the significant population shifts and displacement in the north following the first round in September," the UN agencies for health, WHO, and for children, UNICEF, said in a statement.

UN organizations and partners began phase one in September and have had more than 200 teams on stand-by since 23 October to unroll the campaign's final round, which had been <u>delayed</u> by constant Israeli airstrikes, clashes on the ground and no assurances of the required humanitarian pauses to stop the fighting during the delivery of the vaccines.

Polio had been eradicated in the Gaza Strip 25 years ago, but the ongoing war triggered multiple health crises, with a 10-month-old being diagnosed with the paralysing virus earlier this year, prompting health officials to organize a campaign in the war-torn Israeli-occupied territory...

## ::::::

#### Polio vaccination campaign to resume in northern Gaza

Statement 01 November 2024

EAST JERUSALEM/AMMAN/GENEVA/NEW YORK, 1 November 2024 - "A third phase of the polio vaccination campaign is set to begin tomorrow in part of the northern Gaza Strip after being postponed from 23 October 2024 due to lack of access and assured, comprehensive humanitarian pauses, intense bombardment, and mass evacuation orders. These conditions made it impossible for families to safely bring their children for vaccination and for vaccination teams to perform their duties.

"The humanitarian pause necessary to conduct the campaign has been assured, however, the area of the pause has been substantially reduced compared to the first round of vaccination in northern Gaza, conducted in September 2024. It is now limited to just Gaza City. Though in the past few weeks, at least 100,000 people have been forced to evacuate from North Gaza towards Gaza City for safety, around 15,000 children under ten years in towns in North Gaza like Jabalia, Beit Lahiya and Beit Hanoun still remain inaccessible and will be missed during the campaign, compromising its effectiveness. To interrupt poliovirus transmission, at least 90 per cent of all children in every community and neighbourhood must be vaccinated, which will be challenging to achieve given the situation.

"The final phase of the campaign had aimed to reach an estimated 119,000 children under ten years old in northern Gaza with a second dose of novel oral polio vaccine type 2 (nOPV2). However, achieving this target is now unlikely due to access constraints...

::::::

#### mPox - PHEIC

## WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak

29 October 2024 News release

In October 2024, WHO and partners, in collaboration with Member States, activated the <u>Global Health</u> Emergency Corps (GHEC) for the first time to provide support to countries facing mpox outbreaks.

**GHEC** is a grouping of professionals with the objective of strengthening the response to health emergencies, and a collaboration platform for countries and health emergency networks. It supports countries on their health emergency workforce, the surge deployment of experts and the networking of technical leaders. GHEC was established by WHO in 2023 after the response to the COVID-19 pandemic revealed the need to streamline efforts of existing networks to ensure better-coordinated support to countries.

**"WHO and partners are supporting the government of the Democratic Republic of the Congo and other countries** to implement an integrated approach to case detection, contact tracing, targeted vaccination, clinical and home care, infection prevention and control, community engagement and mobilization, and specialized logistical support," said Dr Mike Ryan, Executive Director of WHO's Health Emergencies Programme. "The GHEC enhances the ability of the many effective responders at national and regional levels to collaborate and ensure the success on the ground in interrupting transmission and reducing suffering."

The first activation of this new support mechanism follows the declaration of mpox as a public health emergency of international concern by WHO Director-General Dr Tedros Adhanom Ghebreyesus on 14 August 2024. Eighteen African countries have reported mpox cases this year, and the rapid spread of clade 1b mpox to at least two other regions has raised concerns about further spread.

In collaboration with the International Association of National Public Health Institutes, GHEC is assessing the emergency workforce capacities in 8 countries affected by the mpox outbreak, including the Democratic Republic of the Congo and Burundi, the two most affected countries.

The assessment has so far identified 22 areas that need strengthening, including epidemiology and surveillance, laboratory capacities, infection prevention and control, risk communication and community engagement. In the Democratic Republic of the Congo, the Health Cluster partners have joined in strengthening the coordination set up by the Ministry of Health under the leadership of the public health emergency operations centre...

#### ::::::

## WHO lists additional mpox diagnostic tests for emergency use

30 October 2024 News release

As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO's EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs).

Polymerase Chain Reaction (PCR) testing, which detects viral DNA, is considered the gold standard for diagnosing mpox infection.

WHO listed the Xpert Mpox, a real-time PCR test manufactured by Cepheid under its EUL procedure, on 25 October. This test is designed for use on compatible GeneXpert systems. The Xpert Mpox test is easy to operate and delivers results in under 40 minutes. Once the cartridge is placed in the system, the process is fully automated, with real-time PCR detecting viral DNA of monkeypox virus clade II. The GeneXpert system is a near-point-of-care testing option, which can support decentralized testing...

::::::

#### **Pandemic Fund**

<u>Pandemic Fund Raises US\$982 million in New Commitments from Governments and an Additional US\$1.8 billion in Co-financing from International Partner Organizations in the First Three Months of its Resource Mobilization Campaign</u>

RIO DE JANEIRO, October 31, 2024 — On the margins of today's G20 Finance and Health Ministers' Joint Meeting held today, the Pandemic Fund announced that it has mobilized US\$2.8 billion over the past three months in **new international financing for low- and middle-income countries to strengthen critical pandemic prevention, preparedness, and response capacities.** The additional resources include commitments from 10 countries amounting to US\$982 million, and cofinancing from international organizations totaling over US\$1.8 billion...

New pledges from sovereign contributors announced today were as follows:

:: AUD 60 million from Australia;

:: US\$12 million from **India**;

:: US\$50 million from **Japan**;

:: NOK 240 million from Norway;

:: EUR 300 thousand from **Portugal**;

:: US\$10 million from **Singapore**; and

:: EUR 25 million from **Spain**.

Portugal is a first-time contributor to the Pandemic Fund. **The United States and Germany reaffirmed their pledges announced at the start of the campaign in July, amounting to up to US\$667 million and EUR 50 million, respectively**. Italy announced its intention to pledge in the same range as its former contribution, EUR 100 million, in the coming months. In addition, the governments of Brazil and Canada signaled their intentions to announce new pledges in the coming months. The European Commission, France, Indonesia, and the Republic of South Africa expressed their strong support for the Pandemic Fund and called for urgent action from sovereign and non-sovereign contributors to provide additional resources.

In the first three months of its resource mobilization campaign, the Pandemic Fund has successfully secured close to 50 percent of its target to mobilize at least US\$2 billion in new pledges to support its <u>strategic plan</u>. The resource mobilization campaign will continue through Spring 2025...

"We are pleased to see so many contributors re-invest in the Pandemic Fund, in recognition of the critical role it is playing in the global finance and health architecture," said Pandemic Fund Board Co-Chairs Dr. Chatib Basri, former Minister of Finance of Indonesia and Dr. Sabin Nsanzimana, Minister of Health of Rwanda. "We urge more countries as well as non-sovereign funders to join these generous investors as soon as possible to ensure that the Pandemic Fund can continue its important work to safeguard humanity from emerging pandemic threats."

Taken together, these pledges and catalytic financial resources are vital to helping low- and middle-income countries implement their obligations under the newly amended International Health Regulations and a future international Pandemic Agreement. To date, 20 African Ministers of Health have issued urgent appeals for donors to step up their direct financial support for the Pandemic Fund...

::::::

## **Pandemic Preparedness**

#### Watch: Is the world ready for the next pandemic?

In a joint event with The Elders, Helen Clark, Ban Ki-moon and other experts discuss the policies needed to prevent the next health catastrophe.

Chatham House

29 October 2024 Event recording - 1 hour watch

The world faces multiple interlinked existential threats such as pandemics and the climate crisis, exacerbated by conflict and extreme poverty. However, the multilateral system is failing to respond with sufficient urgency or impact. As the fifth anniversary of the COVID-19 pandemic approaches, Chatham House and <u>The Elders</u> will discuss the risk of a general slide into complacency.

Amid the expanding outbreak of mpox in Africa, rich countries continue to withhold stockpiled mpox vaccines. The failure to release the required amount is contributing to the diseases spread across the continent.

Meanwhile, the Pandemic Accord negotiations are in overtime, with nations unable to reach agreement over concerns around sovereignty and resource distribution in any future pandemic. Similarly, a proposal to include a UN Emergency Platform in the recent Summit of the Future to strengthen the multilateral response to complex global shocks was shelved due to political deadlock.

Can the world learn from past mistakes and break the cycle of panic and neglect? In today's fractious and polarized geopolitical context, what would it take for leaders to do what's necessary? And why is it so critical to have equity at the heart of any sustainable global response?

Join Chatham House for this event in which the panel discuss key questions including:

- Five years on from COVID-19, who is showing global leadership today in preparing for future pandemics?
- Are international organizations and institutions fit for purpose to respond to pandemics in a multipolar geopolitical environment? How can they best adapt?
- What can be done to clarify and detoxify current debates around sovereignty to improve global pandemic prevention, preparedness and response?

::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

::::::

## WHO & Regional Offices [to 02 Nov 2024]

https://www.who.int/news

Selected News/Announcements/Statements

1 November 2024 Statement

<u>Statement by Principals of the Inter-Agency Standing Committee – Stop the assault on Palestinians in Gaza and on those trying to help them</u>

We the leaders of 15 United Nations and humanitarian organizations urge, yet again, all parties fighting in Gaza to protect civilians, and call on the State of Israel to cease its assault on Gaza and on the humanitarians trying to help...

1 November 2024 News release

Global Model WHO youth delegates urge swift action on pandemic prevention, preparedness and response

1 November 2024 News release

Quadripartite partners organize High-Level One Health meeting in collaboration with Brazil's Ministry of Health at the G20 Summit

The Quadripartite collaboration on One Health – comprising the Food and Agriculture Organization of the United Nations (FAO), the UN Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH) – co-organized the G20 High-Level Meeting on One Health on 30 October 2024. This event featured a panel discussion titled "Creating an Enabling Environment for One Health Implementation," emphasizing the critical need for robust governance and multisectoral coordination to advance the One Health approach, supported by real-life examples from various countries...

The panel discussion aimed to foster dialogue and create an enabling environment for One Health at global, regional, and national levels. It highlighted the necessity of effective governance, multisectoral coordination, legal frameworks, political commitment, and sustainable financing to tackle global health challenges. Ministerial speakers from G20 countries shared valuable insights and experiences, facilitating knowledge exchange to identify collaborative efforts that can enhance impact. Engaging high-level leaders reinforced the commitment of G20 nations to advance One Health implementation and laid the groundwork for future collaboration...

1 November 2024 News release

**G20** health ministers rally support for WHO's Investment Round

1 November 2024 Statement

#### Polio vaccination campaign to resume in northern Gaza

A third phase of the polio vaccination campaign is set to begin tomorrow in part of the northern Gaza Strip after being postponed from 23 October 2024 due to lack of access and assured, comprehensive humanitarian pauses, intense bombardment, and mass evacuation orders. These conditions made it impossible for families to safely bring their children for vaccination and to organize campaign activities...

30 October 2024 News release

WHO lists additional mpox diagnostic tests for emergency use

29 October 2024 News release

WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak

#### Tuberculosis resurges as top infectious disease killer

::::::

#### **WHO Regional Offices**

Selected Press Releases, Announcements

### **WHO African Region**

:: 31 October 2024

African health ministers, delegates adopt declaration on climate change and health

:: 30 October 2024

South Sudan intensifies efforts to curb cholera outbreak

:: 28 October 2024

WHO in Africa, WomenLift Health sign pivotal agreement to strengthen women's leadership in health

#### **WHO Region of the Americas PAHO**

:: 1 Nov 2024

## PAHO to facilitate access to maternal vaccines to protect babies in the Americas from respiratory syncytial virus

Washington, D.C., November 1, 2024 (PAHO) – Starting in the first quarter of 2025, the Pan American Health Organization (PAHO), through its Regional Revolving Funds, will provide countries of the Americas with affordable access to the vaccine against respiratory syncytial virus (RSV), a leading cause of pediatric hospitalization and death from...

:: 1 Nov 2024

## <u>Tuberculosis resurges as top infectious disease killer</u>

New global report shows that while cases continue to rise in the Americas, improvements in diagnosis and treatment are helping to reduce deaths1 November 2024 – The World Health Organization (WHO) published a new report on tuberculosis (TB) revealing that globally, approximately 8.2 million people were newly diagnosed with TB in 2023 - the...

:: 31 Oct 2024

### PAHO issues epidemiological alert for measles cases in the Americas

Washington, DC, October 31, 2024 (PAHO) – The Pan American Health Organization (PAHO) has issued an epidemiological alert due to the recent identification of clusters and cases of measles in the Americas, urging countries to intensify their vaccination and surveillance efforts. In the alert published on Monday, PAHO reported that, in 2024 up to...

:: 29 Oct 2024

## PAHO observes International Day of Care and Support, calling for support for dependent people and their caregivers

Washington, DC, October 29, 2024 (PAHO) – The Pan American Health Organization (PAHO) joins in the observance of the International Day of Care and Support today, to highlight the vital role of care at all stages of life. PAHO urges the implementation of policies that not only support dependent people but also strengthen the care workforce.As...

### **WHO South-East Asia Region SEARO**

No new digest content identified.

## **WHO European Region EURO**

:: 31 October 2024 News release

WHO European Region Member States adopt two landmark health emergency action plans: Preparedness 2.0 strategy and action plan and the Emergency Medical Teams regional action plan 2024–2030

:: 31 October 2024 News release

WHO European Region Member States adopt new vision for resilient and sustainable health systems

:: 30 October 2024 Media release

<u>Dr Hans Henri P. Kluge nominated by Member States to serve as WHO Regional Director for Europe for a second 5-year term</u>

:: 29 October 2024 News release

Advancing the implementation of the One Health approach in the WHO European Region

### WHO Eastern Mediterranean Region EMRO

:: WHO and the UK sign an agreement to support patients from Gaza in Egypt 28 October 2024

#### **WHO Western Pacific Region**

No new digest content identified.

::::::

## **WHO - Emergency situation reports**

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

## **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

1 November 2024 | Marburg virus disease - Rwanda

31 October 2024 | Malaria - Ethiopia

::::::

#### **Weekly Epidemiological Record**

https://www.who.int/publications/journals/weekly-epidemiological-record

Vol. 99, No. 44, pp. 641-652 1 November 2024

PDF: https://iris.who.int/bitstream/handle/10665/379414/WER9944-eng-fre.pdf

:: Routine vaccination coverage – worldwide, 2023

::::::

#### **New WHO Publications**

https://www.who.int/publications/i Selected 29 October 2024 Global tuberculosis report 2024

29 October 2024

<u>Joint external evaluation of the International Health Regulations (2005) core capacities of the United...</u>

29 October 2024

WHO pharmaceuticals newsletter - No. 4, 2024

28 October 2024

Governance of the private healthcare sector in low- and middle-income countries: a scoping review of...

::::::

**USA – HHS, FDA, CDC** 

#### **HHS**

News

No new digest content identified.

#### **FDA**

Press Announcements

FDA Roundup: November 1, 2024

:: Today, the FDA published the FDA Voices: "FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub," by Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER). The FDA Rare Disease Innovation Hub (the Hub) is an FDA crosscenter program that will act as the single point of engagement and connection with outside parties for drug and biological product development and as a forum for CBER and CDER to collaborate on crosscutting rare disease-related issues. Through the Hub, we plan to foster a community at the FDA for open dialogue and knowledge sharing to identify new approaches to drug and biologic development and overcome hurdles that have traditionally impeded progress for rare disease treatments...

#### **FDA VRBPAC**

Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting</u> Announcement - 12/12/2024

CDC/ACIP [U.S.] [to 02 Nov 2024] <a href="http://www.cdc.gov/media/index.html">http://www.cdc.gov/media/index.html</a> <a href="Latest News">Latest News</a> <a href="https://www.cdc.gov/media/index.html">No new digest content identified</a>.

#### **ACIP Meetings**

Next ACIP Meeting February 26-27, 2025

### **MMWR Weekly**

https://www.cdc.gov/mmwr/index2024.html

October 31, 2024 / No. 43

#### **PDF** of this issue

- <u>Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period</u>
   Suzhou City, Jiangsu Province, China, 2018–2023
- <u>Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel National Healthcare Safety Network, United States, 2023–24 Respiratory Virus Season</u>

- <u>Statewide Outbreak of Neisseria meningitidis Serogroup Y, Sequence Type 1466 Virginia, 2022–2024</u>
- Routine Vaccination Coverage Worldwide, 2023

::::::

### **Europe**

## **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news

News & Press Releases

No new digest content identified.

## **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

<u>Increased flu and COVID-19 vaccination coverage recommended for risk groups in EU/EEA</u> ahead of winter season

29 Oct 2024

::::::

Africa CDC [to 02 Nov 2024]

https://africacdc.org/

Press Releases, Statements [Selected]

The change in African vaccine manufacturing landscape

1 November 2024

Statement

Statement on Antigen Rapid Tests for Mpox Diagnosis, 30 October 2024

31 October 2024

Call for Applications

**Call for Applications | The Africa CDC Bingwa Plus Initiative** 

31 October 2024

Strategic Framework

African Vaccine Manufacturing Mapping | Supply and Demand Landscape

30 October 2024

Strategic Framework

Strengthening Cross-Border Surveillance and Information Sharing in Africa

30 October 2024

Press Releases

**Inaugural Global Surveillance Summit 2024, Cape Town, South Africa** 

29 October 2024

::::::

#### China CDC+

http://www.chinacdc.cn/en/

## **National Health Commission of the People's Republic of China** [to 02 Nov 2024]

http://en.nhc.gov.cn/

News

No new digest content identified.

## National Medical Products Administration – PRC [to 02 Nov 2024]

http://english.nmpa.gov.cn/

News

No new digest content identified.

#### **China CDC**

## CCDC Weekly Reports: Current Volume (6)

2024-11-01 / No. 44

PDF of this issue

- <u>Preplanned Studies: Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period Suzhou City, Jiangsu Province, China, 2018–2023</u>
- <u>Preplanned Studies: Social Network Analysis of a Norovirus Outbreak at a Primary School Zhuhai City, Guangdong Province, China, 2023</u>
- Outbreak Reports: Emergence of a New Sublineage of Candida auris Causing Nosocomial Transmissions Beijing Municipality, China, March–September 2023

::::::

## Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

## **Organization Announcements**

### **Paul G. Allen Frontiers Group** [to 02 Nov 2024]

https://alleninstitute.org/news-press/

News

No new digest content identified.

#### **BMGF - Gates Foundation** [to 02 Nov 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements

No new digest content identified.

## **Bill & Melinda Gates Medical Research Institute** [to 02 Nov 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications No new digest content identified.

**CARB-X** [to 02 Nov 2024]

https://carb-x.org/

News

10.31.2024 |

## **CARB-X appoints Andy Soares White as Chief Financial Officer**

CARB-X today announced the appointment of Andy Soares White to Chief Financial Officer (CFO). Soares White will oversee CARB-X's financial operations, ensuring robust fiscal management and strategic allocation of resources.

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 02 Nov 2024]

http://cepi.net/

CEPI News

News

### Immune-boosting bacterial platform could aid nasal vaccines

28 October 2024, OSLO, Norway and STOCKHOLM, Sweden - Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against epidemic and pandemic threats...

## CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 02

Nov 20241

https://cioms.ch/

News; Publications; Events

### **CIOMS Glossary of ICH terms and definitions: Version 7 now available**

Version 7 of the CIOMS Glossary of ICH terms and definitions is now freely available <u>here</u>. It can also be accessed from the ICH webpage <u>here</u>.

#### DARPA - Defense Advanced Research Projects Agency [U.S.] [to 02 Nov 2024

https://www.darpa.mil/news

News

No new digest content identified.

#### **Duke Global Health Innovation Center** [to 02 Nov 2024]

https://dukeghic.org/

News

No new digest content identified.

**EDCTP** [to 02 Nov 2024]

#### http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

No new digest content identified

## **Emory Vaccine Center** [to 02 Nov 2024]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### **European Vaccine Initiative** [to 02 Nov 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

### **Evidence Aid** [to 02 Nov 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

**Evidence Aid: Final farewell - 31 October 2024** 

www.evidenceaid.org

When we announced the news of our closure back in July, we hoped that Evidence Aid summaries would remain accessible and free of charge beyond closure of the charity. We are delighted to be able to announce that from now, the International Rescue Committee are hosting the website, evidenceaid.org and continue to make much of Evidence Aid's existing material available to the public. Should you have any questions relating to the website after 31 October, please contact airbel@rescue.org.

#### Fondation Merieux [to 02 Nov 2024]

http://www.fondation-merieux.org/ News, Events No new digest content identified.

Gavi [to 02 Nov 2024] https://www.gavi.org/ Press Releases 1 November 2024

<u>Cambodia launches national measles-rubella vaccination campaign to protect over 1.5</u> million children

31 October 2024

**Democratic Republic of the Congo launches malaria vaccine into routine immunisation** 

## **GE2P2 Global Foundation** [to 02 Nov 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review October 2024
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 16 Oct 2024 Issue 24

**GHIT Fund** [to 02 Nov 2024]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 02 Nov 2024]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

## **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 02 Nov 2024]

https://www.glopid-r.org/news/ No new digest content identified.

#### **Hilleman Laboratories** [to 02 Nov 2024]

http://www.hilleman-labs.org/

News & Insights

## <u>Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic</u> Partnership to Promote CDMO Services in Cell and Gene Therapy

Singapore, October 30, 2024 — Teijin Limited and Hilleman Laboratories, a biotechnology company based in Singapore, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion in contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.

Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy for the development and manufacturing of cell and gene therapy products, and mutually advance CDMO business activities of respective parties...

## **HHMI - Howard Hughes Medical Institute** [to 02 Nov 2024]

https://www.hhmi.org/news

Press Room

## **Jay Jacobs Elected as HHMI Trustee**

October 29, 2024

Jacobs, former President and Managing Director of global investment management firm PIMCO will join HHMI's Board of Trustees.

## **Human Immunome Project [nee Human Vaccines Project]** [to 02 Nov 2024]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

**IAVI** [to 02 Nov 2024] <a href="https://www.iavi.org/">https://www.iavi.org/</a> *News, Features No new digest content identified.* 

**INSERM** [to 02 Nov 2024] https://www.inserm.fr/en/home/

Press Releases

Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation 25 Oct 2024 |

In celebration of its 60th anniversary, Inserm is emphasizing its scientific collaboration with the United States and Canada. This privileged and fruitful relationship with North America will be highlighted during a day of scientific and institutional exchanges on October 29, 2024, at the French Embassy in Washington, DC. The event will be attended by Professor Didier Samuel, President and CEO of Inserm, along with representatives from numerous partner institutions. The agenda will include the initiation of new collaborations with leading American scientific institutions, the presentation of the 2024 Inserm International Award to a distinguished researcher, the strengthening of Inserm's presence in Washington, DC, and the launch of the Inserm Abroad Network.

## **International Coalition of Medicines Regulatory Authorities [ICMRA]**

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

## ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 02 Nov 2024]

https://www.ich.org/ News/Pubs/Press Releases [Selective] 24 October 2024

ICH E8(R1) General Considerations for Clinical Studies Introductory Training Video now available on the ICH Website

The ICH Secretariat is pleased to announce the publication of ICH E8(R1) General Considerations for Clinical Studies Introductory Training Video.

**ICRC** [to 02 Nov 2024]

https://www.icrc.org/en/whats-new

What's New [Selected]

<u>China: Experts gather to explore Chinese traditions and international humanitarian concepts</u>

29-10-2024 ICRC (Beijing) — On October 25, 2024, humanitarian experts, medical professionals, diplomats, relief practitioners, and scholars convened in Beijing to explore the convergences of Chinese traditions and international humanitarian concepts.

News release 29-10-2024

#### **IFFIm**

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

**IFRC** [to 02 Nov 2024]

http://media.ifrc.org/ifrc/news/press-releases/ Press Releases [Selected] No new digest content identified.

Institut Pasteur [to 02 Nov 2024] https://www.pasteur.fr/en/press-area Press Documents No new digest content identified.

## **ISC / International Science Council** [to 02 Nov 2024]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

## **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected]

**IUIS 2025: Empower the Next Generation of Scientists!** 

October 10, 2024

We need your help to bring 500 early-career scientists from low-and middle-income countries...

**IVAC** [to 02 Nov 2024]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

**IVI** [to 02 Nov 2024]

http://www.ivi.int/

IVI News & Announcements

IVI conducts 2024 Introductory Course for Standard Practice (GxP) to strengthen manufacturing capabilities of high-quality vaccines and biologics in LMICs

Third GxP course to train 183 participants from 42 countries and 13 trainees from Korea to enhance global vaccine equity

October 29, 2024

## **Johns Hopkins Center for Health Security** [to 02 Nov 2024]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

## MSF/Médecins Sans Frontières [to 02 Nov 2024]

http://www.msf.org/ Latest [Selected Announcements] No new digest content identified.

## National Academy of Medicine - USA [to 02 Nov 2024]

https://nam.edu/programs/
News [Selected]
No new digest content identified.

## National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 02 Nov 2024]

https://www.nationalacademies.org/newsroom

News

## New International Bioeconomy Forum Strengthens Engagement Between U.S. and India on Promoting and Protecting the Bioeconomy

Our International Bioeconomy Roundtable held an in-person event at the Global Bio-India 2024 conference in New Delhi, India, to discuss the scope of a new National Academies initiative, the International Bioeconomy Forum.

Date

2024-10-28

#### National Vaccine Program Office - U.S. HHS [to 02 Nov 2024]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No new digest content identified.

NIH [to 02 Nov 2024] http://www.nih.gov/

News Releases

#### NIH trial of rectal microbicide for HIV prevention begins in the United States

October 31, 2024 — Study will assess safety and acceptability of rectal douche for pre-exposure prophylaxis.

**PATH** [to 02 Nov 2024]

https://www.path.org/media-center/

Newsroom

## <u>PATH and Bio-Manguinhos/Fiocruz commit to boosting technological platforms and increasing local production</u>

... a new collaboration aimed at accelerating the innovation, production, and access to vaccines, diagnostics, and biopharmaceuticals in Brazil, Latin America, and the Caribbean...

Published: October 2024

## <u>PATH shares topline results from a Phase 3 study of an injectable rotavirus vaccine</u> candidate

The trial aimed to determine how well a new, injectable, non-replicating rotavirus vaccine candidate works, compared to a licensed oral rotavirus vaccine in preventing infant diarrhea.

Published: October 2024

Announcement

#### **Sabin Vaccine Institute** [to 02 Nov 2024]

https://www.sabin.org/press/ Latest News & Press Releases

## Sabin Sends More Marburg Vaccines for Rwanda's Outbreak

October 31, 2024

In continued collaboration with Rwanda to address the Marburg virus outbreak, the Sabin Vaccine Institute has dispatched approximately 1,000 additional investigational vaccine doses for a randomized clinical trial arm within the ongoing open-label study. More than 1,500 frontline workers have already been vaccinated in Rwanda with the Sabin vaccine.

#### **UNAIDS** [to 02 Nov 2024]

http://www.unaids.org/en News, Stories, Updates Press release

## <u>G20 commits to fighting the inequalities driving AIDS and other pandemics. Leaders back</u> new initiative to widen production of medicines in every region

RIO DE JANEIRO, BRAZIL, 1 November 2024 — Ministers at the G20 Ministerial in Rio De Janeiro have made new commitments to tackle AIDS and other pandemics, through addressing the inequalities driving them, both globally and nationally.

The commitments have been welcomed as a potential breakthrough against AIDS and other pandemics by international experts including Nobel Prize Winning Economist Joseph E. Stiglitz, world-leading epidemiologist Sir Michael Marmot, and former First Lady of Namibia Monica Geingos. The experts, who are the Co-Chairs of the Global Council on Inequality, AIDS, and Pandemics established by UNAIDS, have been in Brazil as part of the Council's engagement of the G20.

G20 leaders have committed, for the first time, to prepare to confront future pandemics by tackling the inequalities which drive them—addressing the social determinants driving pandemics. Committing to measure and address social determinants—factors like education, income inequality, and discrimination that have proven as important to pandemic preparedness and response as medical care—reflects an important step in addressing key drivers of health emergencies...

#### **UNICEF** [to 02 Nov 2024]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements Statement 01 November 2024

### Stop the assault on Palestinians in Gaza and on those trying to help them

NEW YORK/GENEVA/ROME, 1 November 2024 – "We the leaders of 15 United Nations and humanitarian organizations urge, yet again, all parties fighting in Gaza to protect civilians, and call on the State of Israel to cease its assault on Gaza and on the humanitarians trying to help. "The situation unfolding in Nor...

Statement 01 November 2024

## Polio vaccination campaign to resume in northern Gaza

EAST JERUSALEM/AMMAN/GENEVA/NEW YORK; 1 November 2024 - "A third phase of the polio vaccination campaign is set to begin tomorrow in part of the northern Gaza Strip after being postponed from 23 October 2024 due to lack of access and assured, comprehensive humanitarian pauses, intense bombardment, and mass ev...

Unitaid [to 02 Nov 2024] https://unitaid.org/ Featured News 01 November 2024

## **Unitaid welcomes G20 Health Working Group Ministerial Declarations ahead of COP29**

Rio de Janeiro, 1 November 2024 – Unitaid welcomes yesterday's <u>G20 Health Working Group Ministerial Declaration on Climate Change, Health and Equity, and on One Health</u> and the <u>Rio de Janeiro Declaration of the G20 Health Ministers</u>. These declarations underscore the urgent need for resilient and equitable health systems that can adapt to the growing challenges of climate change, pandemics, and antimicrobial resistance (AMR), prioritizing sustainable, low-carbon solutions and enhanced access to essential health services for vulnerable communities. Unitaid is committed to advancing these shared objectives through its work to make lifesaving health products accessible and affordable for low- and middle-income countries, building health systems that can better withstand the pressures of future pandemics and climate-related challenges...

## **Vaccine Equity Cooperative [nee Initiative]** [to 02 Nov 2024]

https://vaccineequitycooperative.org/news/ News Website not responding at inquiry.

#### **Vaccination Acceptance & Demand Initiative [Sabin)** [to 02 Nov 2024]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

#### **Vaccine Confidence Project** [to 02 Nov 2024]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

#### **Vaccine Education Center – Children's Hospital of Philadelphia** [to 02 Nov 2024]

http://www.chop.edu/centers-programs/vaccine-education-center
News

#### **Vaccine Update for Providers**

October 2024

Announcements: December webinar, new RSV Q&A sheets, updated vaccine safety booklet, and new website section on vaccine ingredients

Wellcome Trust [to 02 Nov 2024]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

#### **The Wistar Institute** [to 02 Nov 2024]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

#### World Bank [to 02 Nov 2024]

http://www.worldbank.org/en/news/all

All News [Selected]

<u>Pandemic Fund Raises US\$982 million in New Commitments from Governments and an Additional US\$1.8 billion in Co-financing from International Partner Organizations in the First Three Months of its Resource Mobilization Campaign</u>

RIO DE JANEIRO, October 31, 2024 — On the margins of today's G20 Finance and Health Ministers' Joint Meeting held today, the Pandemic Fund announced that it has mobilized US\$2.8 billion over the past three...

Date: October 31, 2024 Type: Press Release

## WFPHA: World Federation of Public Health Associations [to 02 Nov 2024]

https://www.wfpha.org/

Blog, Events

No new digest content identified.

#### World Medical Association [WMA] [to 02 Nov 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

No new digest content identified.

#### **World Organisation for Animal Health [OIE]** [to 02 Nov 2024]

https://www.oie.int/ Press Releases, Statements Global Events No new digest content identified.

::::::

### **ARM [Alliance for Regenerative Medicine]** [to 02 Nov 2024]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 02 Nov 2024]

https://www.bio.org/press-releases

No new digest announcements identified.

## **DCVMN – Developing Country Vaccine Manufacturers Network** [to 02 Nov 2024]

http://www.dcvmn.org/
News; Upcoming events

No new digest announcements identified.

## ICBA – International Council of Biotechnology Associations [to 02 Nov 2024]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

## **IFPMA** [to 02 Nov 2024]

https://ifpma.org/

News, Statements [Selected] Statement 2 November 2024

## <u>Conclusion of COP16 Negotiations on Multilateral Mechanism for Benefit-Sharing of DSI</u> By IFPMA

On the conclusion of the COP16 negotiations on proposals to include digital sequence information (DSI) within the scope of the Convention of Biodiversity (CBD), IFPMA Director General, Dr. David Reddy, said:

"The pharmaceutical industry has long supported the Convention on Biological Diversity's objective to protect our natural world and will continue to engage in discussions on mechanisms that safeguard biodiversity while fostering scientific research and innovation".

"The decision adopted today does not get the balance right between the intended benefits of such a mechanism and the significant costs to society and science that it has the potential to create".

"The ability to rapidly use scientific data known as "digital sequence information" (DSI) is essential for developing new medicines and vaccines. Any new system should not introduce further conditions on how scientists access such data and add to a complex web of regulation, taxation and other obligations for the whole R&D ecosystem – including on academia and biotech companies. New technologies that use DSI can contribute to conservation and sustainable use of biodiversity and should be encouraged".

"Ahead of COP17, it is critical that governments work to ensure the implementation of any new mechanism on digital sequence information does not stifle the medical research and innovation that can bring the next wave of medical progress to people around the world."

Statement 31 Oct 2024

## 74th WHO Regional Committee for Europe: Harnessing innovation for public health in the WHO European Region 2025-2030

On 31 October 2024 in Copenhagen, Denmark, IFPMA delivered a statement at the 74th WHO Regional Committee for Europe on harnessing innovation for public health in the WHO European Region 2025-2030.

Statement 31 Oct 2024

## 74th WHO Regional Committee for Europe: Framework for resilient and sustainable health systems in the WHO European Region

On 31 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th Regional Committee for Europe on the framework for resilient and sustainable health systems in the WHO European Region.

Statement 29 Oct 2024

## 74th WHO Regional Committee for Europe: WHO/Europe Access to Novel Medicines Platform

On 29 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th WHO Regional Committee for Europe on the WHO/Europe Access to Novel Medicines Platform.

## **International Alliance of Patients' Organizations – IAPO** [to 02 Nov 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

## **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

**PhRMA** [to 02 Nov 2024]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

#### Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

#### **AstraZeneca**

Press Releases - No new digest announcements identified

#### **Bavarian Nordic**

Latest News

October 29, 2024

## <u>First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for</u> Bavarian Nordic's Mpox Vaccine

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age.

#### **Bharat Biotech**

<u>Press Releases</u> - No new digest announcements identified

#### **BioCubaFarma** – Cuba

Últimas Noticias - No new digest announcements identified

#### **Biological E**

News - No new digest announcements identified

#### **BioNTech**

<u>Press Releases</u> - No new digest announcements identified

## **Boehringer**

<u>Press Releases</u> - No new digest announcements identified

#### **CanSinoBIO**

News - Website not responding at inquiry

#### **CIGB**

Latest News - No new digest announcements identified.

### Cinnagen

<u>Recent News</u> - No new digest announcements identified.

#### **Clover Biopharmaceuticals** – China

News

Oct 29, 2024

## <u>Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY</u>

Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019

#### Curevac

News

October 28, 2024

## <u>CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting</u>

CureVac will present, among other data, extended preliminary immunogenicity results from Part A of the dose escalation phase of its ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma.

## **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

#### **GSK**

Press releases for media

29 October 2024

## GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

## EuBiologics, S Korea

News - No new digest announcements identified.

#### IMBCAMS, China

Home - Website not responding at inquiry.

#### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified.

#### Merck

<u>News releases</u> - No new digest announcements identified

#### Moderna

<u>Press Releases</u> - No new digest announcements identified

## Nanogen

News - No new digest announcements identified

#### **Novartis**

News - No new digest announcements identified.

#### **Novavax**

Press Releases - No new digest announcements identified.

#### **Pfizer**

Recent Press Releases - No new digest announcements identified.

#### R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

#### **Sanofi Pasteur**

Press Releases - No new digest announcements identified.

## Sinopharm/WIBPBIBP

News - No new digest announcements identified

#### Sinovac

Press Releases - No new digest announcements identified.

#### **SK Biosciences**

Press Releases - No new digest announcements identified.

### **Takeda**

Newsroom - No new digest announcements identified.

#### **Valneva**

<u>Press Releases</u> - No new digest announcements identified

## **Vector State Research Centre of Viralogy and Biotechnology**

Home - [Website not responding [404 error]

## WestVac Biopharma

Media - No new digest announcements identified.

### Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: <u>Journal Watch</u> :: Pre-Print Servers

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

## **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 4 <a href="https://www.tandfonline.com/toc/uabr21/current">https://www.tandfonline.com/toc/uabr21/current</a> [Reviewed earlier]

#### **AMA Journal of Ethics**

Volume 26, Number 11: E823-895

https://journalofethics.ama-assn.org/issue/peace-health-care

#### Peace in Health Care

Clinicians are carefully trained to incorporate and routinize what they do together every day, over and over again: health care professionalism has always been and is a practice. While so-called "medical shows" glamorize high-stakes, emotional health care situations, skilled clinicians generally strive to mitigate crises and control any variables they can, restore homeostasis, and promote stability and wellness in the lives of ill, injured patients. As a culture, we probably do not benefit much when health care organizations are misappropriated and misrepresented as sites of dramatic entertainment. In reality, patients, their loved ones, and their clinicians need health care organizations to be places of peace. This theme issue investigates what it means to establish and maintain health care as an enterprise known less for stress and more for healing.

#### **American Journal of Human Genetics**

Oct 03, 2024 Volume 111 Issue 10 p2071-2306

https://www.cell.com/ajhg/current

#### This month in *The Journal*

Alyson B. Barnes, Kylee L. Spencer

Genome-wide association studies have shown that the effect sizes of many causal variants are strongly correlated across ancestries, but this is not true for all variants. Some differences could be explained by variation in gene regulation, but it has been challenging to determine whether ancestry-specific levels of gene expression are due to differences in allele frequencies, environmental effects, interplay between the two, or simply false positives. In this issue, Wang et al. identify genes differentially expressed across ancestries (ancDE) by leveraging single-cell RNA-sequencing data for individuals with either East Asian or European ancestries.

[Reviewed earlier]

#### **American Journal of Infection Control**

November 2024 Volume 52 Issue 11 p1227-1344 http://www.ajicjournal.org/current [Reviewed earlier]

### **American Journal of Preventive Medicine**

November 2024 Volume 67 Issue 5 p641-802 <a href="https://www.ajpmonline.org/current">https://www.ajpmonline.org/current</a> [Reviewed earlier]

#### **American Journal of Public Health**

November 2024 114(11) <a href="http://ajph.aphapublications.org/toc/ajph/current">http://ajph.aphapublications.org/toc/ajph/current</a> [Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 4 (Oct 2024) <a href="https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-3.xml">https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-3.xml</a> [Reviewed earlier]

#### **Annals of Internal Medicine**

October 2024 Volume 177, Issue 10 <a href="https://www.acpjournals.org/toc/aim/current">https://www.acpjournals.org/toc/aim/current</a> [Reviewed earlier]

#### **Artificial Intelligence – An International Journal**

Volume 336 November 2024 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/336/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/336/suppl/C</a> [New issue; No digest content identified]

### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 02 Nov 2024)

The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review

Dynamic transmission models are often used to provide epidemiological guidance for pandemic policy decisions. However, how economic evaluation is typically incorporated into this technique to generate cost-eff...

Authors: Shania Rossiter, Samantha Howe, Joshua Szanyi, James M. Trauer, Tim Wilson and Tony Blakely

Citation: Cost Effectiveness and Resource Allocation 2024 22:77

Content type: Research Published on: 1 November 2024

## <u>Financing immunisation in Kenya: examining bottlenecks in health sector planning and budgeting at the decentralised level</u>

Decentralisation has increasingly been adopted by countries as an important health sector reform aimed at increasing community participation in decision making while enhancing swift response at decentralised I...

Authors: Alex Olateju Adjagba, James Odhiambo Oguta, Catherine Akoth, Elvis Omondi Achach

Wambiya, Justice Nonvignon and Debra Jackson

Citation: Cost Effectiveness and Resource Allocation 2024 22:76

Content type: Research Published on: 29 October 2024

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content

(Accessed 02 Nov 2024)

## <u>Cost of integrated immunization campaigns in Nigeria and Sierra Leone: bottom-up costing</u> studies

To improve the efficient use of scarce resources, low- and middle-income countries and development partners are increasingly encouraged to deliver multiple vaccines and other interventions in a single integrat...

Authors: Laura Boonstoppel, Flavia Moi, Christina Banks, Florence Sibeudu, Divine Obodoechi, Kyle

Borces, Obinna Onwujekwe and Logan Brenzel

Citation: BMC Health Services Research 2024 24:1334 Content type: Research Published on: 1 November 2024

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 02 Nov 2024)

## <u>Sexually transmitted infections in the middle east and North Africa: comprehensive</u> systematic review and meta-analysis

Globally, sexually transmitted infections (STIs) collectively cause 2.3 million deaths and 1.2 million cases of cancer annually. However, the epidemiology of STIs in the Middle East and North Africa (MENA) is ...

Authors: Dalia Obeid, Feda Alsuwairi, Rawan Alnemari, Ahmed Al-Qahtani, Wesam Kurdi, Manal

Alfareh, Madain Alsanea, Maha Alabdulkareem, Layla Alharbi and Fatimah S. Alhamlan

Citation: BMC Infectious Diseases 2024 24:1229

Content type: Research Published on: 1 November 2024

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 02 Nov 2024) [No new digest content identified]

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 02 Nov 2024) [No new digest content identified]

## **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 02 Nov 2024) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 02 Nov 2024) [No new digest content identified]

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 02 Nov 2024) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

October 2024 - Volume 29 - 5 https://ebm.bmj.com/content/29/5 [Reviewed earlier]

#### **BMJ Global Health**

October 2024 - Volume 9 - 10 https://gh.bmj.com/content/9/10 Practice

riactice

<u>Political engagement: a key pillar in revitalisation of polio and routine immunisation programmes in the Democratic Republic of the Congo</u> (22 October, 2024)

Roger Kamba, Amine El Mourid, Raoul Mpoyi Ngambwa, Donat Chungu Salumu, Jean-Bernard Le Gargasson, Daniel Nacoulma, Marcellin Nimpa Mengouo, Nolan Meyer, Christophe Luhata, Nicole A Hoff, Hadia Samaha, Collard Madika, Christelle Mputu, Sylvia Tangney, Cyril Nogier, Chris Diomi, Sydney Merritt, Emma Din, Polydor Kabila, Annabelle Burgett, Didier Nyombo, Emmanuelle Assy, Dalau Mukadi Nkamba, Lora Bertin, Trad Hatton, Didine Kaba, Anne W Rimoin, Elisabeth Mukamba Musenga, Aimé Cikomola, Guillaume Ngoie Mwamba, Sylvain Yuman Ramazani, Kamel Senouci, Magdalena Robert

#### Commentary

Malaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa (9 October, 2024)

Alemayehu Lelisa Duga, Ngashi Ngongo, Mosoka Papa Fallah, Albert Figueras, Carlos Kilowe, Jibril Murtala, Kizito Kayumba, Tedi Angasa, Aminu Kuba, Patrick Chanda Kabwe, Nebiyu Dereje, Tajudeen Raji, Nicaise Ndembi, Jean Kaseya

### Original research

<u>Seroprevalence of seven arboviruses of public health importance in sub-Saharan Africa: a systematic review and meta-analysis</u> (31 October, 2024)

Salifou Talassone Bangoura, Sidikiba Sidibé, Lanceï Kaba, Aminata Mbaye, Castro Gbêmêmali Hounmenou, Alhassane Diallo, Saidouba Cherif Camara, Maladho Diaby, Kadio Jean-Jacques Olivier Kadio, Eric D'Ortenzio, Alioune Camara, Philippe Vanhems, Alexandre Delamou, Eric Delaporte, Alpha-Kabinet Keita, Michèle Ottmann, Abdoulaye Touré, Nagham Khanafer

## <u>Long Covid: a global health issue – a prospective, cohort study set in four continents</u> (21 October, 2024)

Ekaterina Pazukhina, Esteban Garcia-Gallo, Luis Felipe Reyes, Anders Benjamin Kildal, Waasila Jassat, Murray Dryden, Jan Cato Holter, Allegra Chatterjee, Kyle Gomez, Arne Søraas, Matteo Puntoni, Nicola Latronico, Fernando A Bozza, Michael Edelstein, Bronner P Gonçalves, Christiana Kartsonaki, Oksana Kruglova, Sérgio Gaião, Yock Ping Chow, Yash Doshi, Sara Isabel Duque Vallejo, Elsa D Ibáñez-Prada, Yuli V Fuentes, Claire Hastie, Margaret E O'Hara, Valeria Balan, Tigist Menkir, Laura Merson, Sadie Kelly, Barbara Wanjiru Citarella, Malcolm G Semple, Janet T Scott, Daniel Munblit, Louise Sigfrid

#### **Bulletin of the Atomic Scientists**

September 2024 https://thebulletin.org/magazine/2024-09/ [Reviewed earlier]

## **Bulletin of the World Health Organization**

Volume 102(10); 2024 Oct 1 <a href="https://www.ncbi.nlm.nih.gov/pmc/issues/471305/">https://www.ncbi.nlm.nih.gov/pmc/issues/471305/</a> [Reviewed earlier]

#### Cell

Oct 31, 2024 Volume 187 Issue 22 p6125-6414 <a href="https://www.cell.com/cell/current">https://www.cell.com/cell/current</a>
50th Anniversary
Featured Article

## **Empowering biomedical discovery with AI agents**

Shanghua Gao, et al.

Open Access

By combining human creativity and subject expertise with the power and potential of artificial intelligence, "AI systems" will help enable powerful discoveries across the biomedical sciences.

## **Child Care, Health and Development**

Volume 50, Issue 6 November 2024 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a> [Reviewed earlier]

#### **Clinical Pharmacology & Therapeutics**

Volume 116, Issue 5 Pages: 1143-1351 November 2024 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">Editoria/</a> Free Access

Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration

Rebecca A. Miksad Pages: 1153-1155

First Published: 15 October 2024

State of the Art Review Open Access

Real-World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases

Stefanie Prilla, et al. Pages: 1188-1197

First Published: 04 July 2024

#### **Clinical Therapeutics**

October 2024 Volume 46 Issue 10 p727-824 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

#### **Clinical Trials**

Volume 21 Issue 5, October 2024 https://journals.sagepub.com/toc/ctja/21/5 [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 02 Nov 2024] [No new digest content identified]

## **Contemporary Clinical Trials**

Volume 146 November 2024

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/146/suppl/C

Review article Abstract only

## **Enhancing clinical drug trial monitoring with blockchain technology**

Poonam Kushwaha, Nidhi Srivastava, Shom Prakash Kushwaha

Article 107684

Research article Abstract only

## <u>Significant delays exist in industry-sponsored pediatric clinical drug trial start-up and</u> enrollment processes

Angie Price, Hannah Simmons, Emily Gehring, Lauren Davis, ... Steven J. Steiner Article 107701

#### The CRISPR Journal

Volume 7, Issue 5 / October 2024 https://www.liebertpub.com/toc/crispr/7/5 [Reviewed earlier]

## **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023 <a href="https://link.springer.com/journal/40142/volumes-and-issues/11-3">https://link.springer.com/journal/40142/volumes-and-issues/11-3</a> [Reviewed earlier]

## **Current Medical Research and Opinion**

Volume 40, Issue 10 2024

#### https://www.tandfonline.com/toc/icmo20/current

[New issue; No digest content identified]

## **Current Opinion in Infectious Diseases**

December 2024 - Volume 37 - Issue 6

https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

VIRAL: Edited by Michelle K. Yong

### Therapeutic agents for the treatment of human mpox

Braddick, Maxwell; Singh, Kasha Priya

Current Opinion in Infectious Diseases. 37(6):518-525, December 2024.

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258

[Accessed 02 Nov 2024]

[No new digest content identified]

## **Developing World Bioethics**

Volume 24, Issue 3 Pages: 135-261 September 2024 https://onlinelibrary.wiley.com/toc/14718847/current

[Reviewed earlier]

## **Development in Practice**

Volume 34, Issue 6, 2024

https://www.tandfonline.com/toc/cdip20/34/6

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 5 September 2024

https://onlinelibrary.wiley.com/toc/14677679/current

[Reviewed earlier]

#### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-

<u>issue</u>

[Reviewed earlier]

#### **Disasters**

Volume 48, Issue 4 October 2024

https://onlinelibrary.wiley.com/toc/14677717/2024/48/4

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 10 10 October 2024

## https://www.embopress.org/toc/14693178/current

[Reviewed earlier]

## **Emerging Infectious Diseases**

Volume 30, Number 11—November 2024 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

## **Epidemics**

Volume 48 September 2024 <a href="https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C</a> [Reviewed earlier]

## **Epidemiology and Infection**

Volume 152 - 2024

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

#### **Ethics & Human Research**

Volume 46, Issue 5 Pages: 1-42 September–October 2024 *Enrolling invested parties in research :: Research on social networking sites* [Reviewed earlier]

#### **Ethics & International Affairs**

Volume 38 - Issue 1 - Spring 2024 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

#### **Ethics, Medicine and Public Health**

Volume 31 (December 2023) <a href="https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C">https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C</a> [Reviewed earlier]

#### The European Journal of Public Health

Volume 34, Issue 5, October 2024 https://academic.oup.com/eurpub/issue/34/5 [Reviewed earlier]

### **Expert Review of Vaccines**

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

## **Foreign Affairs**

November/December 2024 Volume 103, Number 6 <a href="https://www.foreignaffairs.com/issues/2023/103/6">https://www.foreignaffairs.com/issues/2023/103/6</a> [New issue; No digest content identified]

## **Forum for Development Studies**

Volume 51, 2024 - Issue 3 <a href="http://www.tandfonline.com/toc/sfds20/current">http://www.tandfonline.com/toc/sfds20/current</a> [Reviewed earlier]

#### **Frontiers in Medicine**

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237 [Accessed 02 Nov 2024]

Mini Review Published on 29 Oct 2024

<u>Large language models in patient education: a scoping review of applications in medicine</u> Serhat Aydin, et al.

Introduction: Large Language Models (LLMs) are sophisticated algorithms that analyze and generate vast amounts of textual data, mimicking human communication. Notable LLMs include GPT-40 by Open AI, Claude 3.5 Sonnet by Anthropic, and Gemini by Google. This scoping review aims to synthesize the current applications and potential uses of LLMs in patient education and engagement. Materials and methods: Following the PRISMA-ScR checklist and methodologies by Arksey, O'Malley, and Levac, we conducted a scoping review. We searched PubMed in June 2024, using keywords and MeSH terms related to LLMs and patient education. Two authors conducted the initial screening, and discrepancies were resolved by consensus. We employed thematic analysis to address our primary research question.

Results: The review identified 201 studies, predominantly from the United States (58.2%). Six themes emerged: generating patient education materials, interpreting medical information, providing lifestyle recommendations, supporting customized medication use, offering perioperative care instructions, and optimizing doctor-patient interaction. LLMs were found to provide accurate responses to patient queries, enhance existing educational materials, and translate medical information into patient-friendly language. However, challenges such as readability, accuracy, and potential biases were noted. Discussion: LLMs demonstrate significant potential in patient education and engagement by creating accessible educational materials, interpreting complex medical information, and enhancing communication between patients and healthcare providers. Nonetheless, issues related to the accuracy and readability of LLM-generated content, as well as ethical concerns, require further research and development. Future studies should focus on improving LLMs and ensuring content reliability while addressing ethical considerations.

## **Genetics in Medicines**

Volume 26, Issue 10 October 2024 <a href="https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/10">https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/10</a> [Reviewed earlier]

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 02 Nov 2024] [No new digest content identified]

#### **Global Health Action**

Volume 17, Issue 1 (2024) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

# **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 5 October 29, 2024 http://www.ghspjournal.org/content/current PROGRAM CASE STUDIES

# <u>Strengthening Capacity for Tailored Immunization Programs Using Adult Learning</u> Principles: A Case Study from Nigeria

Chisom Obi-Jeff, Funmilayo Oguntimehin, Abduljaleel Adejumo, Abdulrahman Ibrahim, Olympus Ade-Banjo, Dan Gadzama, Nicholas Okoli, Chidera Obi, Rachael Olorupo, Ifeyinwa Martins, Amina Usman, Audu Joy, Tanko Chadwafwa and Anthony Onimisi

Global Health: Science and Practice October 2024, 12(5):e2300465; https://doi.org/10.9745/GHSP-D-23-00465

Incorporating participatory approaches such as adult learning principles in training PMs and HCWs improves their knowledge and skills in effectively engaging the communities and co-designing tailored interventions to improve vaccination uptake.

## Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\_desc

[Accessed 02 Nov 2024]

[No new digest content identified]

## **Global Public Health**

Volume 19, Issue 1 (2024) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 02 Nov 2024] [No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 1, June 2024 https://www.hhrjournal.org/volume-26-issue-1-june-2024/ SPECIAL SECTION — COMMEMORATING 30 YEARS [Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 2 - April 2024

https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

# **Health Policy and Planning**

Volume 39, Issue 9, November 2024 https://academic.oup.com/heapol/issue/39/9 [Reviewed earlier]

# **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 02 Nov 2024] [No new digest content identified]

## **Human Gene Therapy**

Volume 35, Issue 19-20 / October 2024 <a href="https://www.liebertpub.com/toc/hum/35/19-20">https://www.liebertpub.com/toc/hum/35/19-20</a> [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/ Featured Publications [No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList Selected Content [Reviewed earlier]

### **Immunity**

Oct 08, 2024 Volume 57 Issue 10 p2251-2482 <a href="https://www.cell.com/immunity/current">https://www.cell.com/immunity/current</a> [Reviewed earlier]

## **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 02 Nov 2024] [No new digest content identified]

## **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 02 Nov 2024] [No new digest content identified]

#### **International Health**

Volume 16, Issue 5, September 2024 <a href="https://academic.oup.com/inthealth/issue/16/5">https://academic.oup.com/inthealth/issue/16/5</a> [Reviewed earlier]

## **International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024): <a href="https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml">https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml</a>

\*\*Special Issue on Inter-State Communications

\*Table of Contents

[Reviewed earlier]

# **International Journal of Community Medicine and Public Health**

Vol. 11 No. 10 (2024): October 2024 <a href="https://www.ijcmph.com/index.php/ijcmph/issue/view/117">https://www.ijcmph.com/index.php/ijcmph/issue/view/117</a> [Reviewed earlier]

## **International Journal of Epidemiology**

Volume 53, Issue 5, October 2024 https://academic.oup.com/ije/issue/53/5 Original articles

<u>Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using</u> sentinel surveillance in South Africa

Nicola Chiwandire and others

# **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024 <a href="https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4">https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4</a> Table of contents [Reviewed earlier]

#### **JAMA**

October 22/29, 2024, Vol 332, No. 16, Pages 1315-1404 <a href="https://jamanetwork.com/journals/jama/currentissue">https://jamanetwork.com/journals/jama/currentissue</a> [Reviewed earlier]

#### **JAMA Health Forum**

October 2024, Vol 5, No. 10 <a href="https://jamanetwork.com/journals/jama-health-forum/issue">https://jamanetwork.com/journals/jama-health-forum/issue</a> [Reviewed earlier]

#### **JAMA Pediatrics**

October 2024, Vol 178, No. 10, Pages 959-1086 https://jamanetwork.com/journals/jamapediatrics/currentissue

# [Reviewed earlier]

## **JBI Evidence Synthesis**

October 2024 - Volume 22 - Issue 10

https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

Editorial

# From chaos to clarity: how COVID-19 exposed the urgent need for better evidence synthesis

Stone, Amy E.L.; Koshy-Chenthittayil, Sherli; DeArmond, Megan JBI Evidence Synthesis. 22(10):1937-1938, October 2024.

#### **Journal of Adolescent Health**

October 2024 Volume 75 Issue 4 p525-690 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [Reviewed earlier]

# **Journal of Artificial Intelligence Research**

Vol. 81 (2024)

https://www.jair.org/index.php/jair

**Contents** 

[Reviewed earlier]

## **Journal of Community Health**

Volume 49, Issue 5 October 2024 <a href="https://link.springer.com/journal/10900/volumes-and-issues/49-5">https://link.springer.com/journal/10900/volumes-and-issues/49-5</a> [Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

<a href="https://www.cmro.in/index.php/jcmro/issue/view/75">https://www.cmro.in/index.php/jcmro/issue/view/75</a>

[Reviewed earlier]

# **Journal of Development Economics**

Volume 171 October 2024

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/171/suppl/C [New issue; No digest content identified]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 3, July 2024

http://journals.sagepub.com/toc/jre/current

Special Issues in Research and IRB/REC Functioning, Including the use of AI

[Reviewed earlier]

# **Journal of Epidemiology & Community Health**

October 2024 - Volume 78 - 10 https://jech.bmj.com/content/78/10 [Reviewed earlier]

## **Journal of Evidence-Based Medicine**

Volume 17, Issue 3 Pages: 469-687 September 2024 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

### **Journal of Global Ethics**

Volume 20, Issue 2 (2024)
<a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a>

Special Issue: Climate Justice and the Global Development Crisis.

Guest Editors: Anna Malavisi, Tom Hilde, and Krushil Watene

[Reviewed earlier]

## **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 3, August 2024 https://muse.jhu.edu/issue/52935 Table of Contents [Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 26, Issue 5 October 2024 https://link.springer.com/journal/10903/volumes-and-issues/26-5 [Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 4 https://www.tandfonline.com/toc/wimm20/current [New issue; No digest content identified]

## **Journal of International Development**

Volume 36, Issue 7 Pages: 3-2866 October 2024 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

### **Journal of Medical Ethics**

October 2024 - Volume 50 - 10 http://jme.bmj.com/content/current [Reviewed earlier]

#### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024) https://institutionalrepository.aah.org/jpcrr/ [New issue; No digest content identified]

### The Journal of Pediatrics

Volume 273 October 2024 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/273/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/273/suppl/C</a> [Reviewed earlier]

## **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) <a href="https://www.tandfonline.com/toc/jppp20/17/1">https://www.tandfonline.com/toc/jppp20/17/1</a> [Reviewed earlier]

# **Journal of Public Health Management & Practice**

September/October 2024 - Volume 30 - Issue 5 <a href="https://journals.lww.com/jphmp/pages/currenttoc.aspx">https://journals.lww.com/jphmp/pages/currenttoc.aspx</a> [Reviewed earlier]

## **Journal of Public Health Policy**

Volume 45, issue 3, September 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-3 [Reviewed earlier]

## Journal of the Royal Society - Interface

October 2024 Volume 21 Issue 219 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> [Reviewed earlier]

#### **Journal of Travel Medicine**

Volume 31, Issue 7, October 2024 <a href="https://academic.oup.com/jtm/issue">https://academic.oup.com/jtm/issue</a> [Reviewed earlier]

## **Journal of Virology**

Volume 98 Number 9 September 2024 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### The Lancet

Nov 02, 2024 Volume 404 Number 10464 p1701-1782 https://www.thelancet.com/journals/lancet/issue/current

#### Editorial

## **Hope for rare diseases**

The Lancet

Advocates for action on rare diseases are having a moment. Oct 28 saw the launch of the <u>European Rare Diseases Research Alliance</u>, an ambitious initiative with a substantial budget of €380 million that unites more than 170 organisations to drive research in prevention, diagnosis, and treatment of rare diseases. This development follows the 2021 UN Resolution on Addressing the Challenges of Persons Living with a Rare Disease and their Families, which put addressing the needs of people with rare diseases—in terms of health, employment, education, poverty, and gender equity—on the highest political agenda. Now, in a push to address disparities in care, research, and treatment, the organisation Rare Diseases International, along with Egypt, Qatar, France, Malaysia, Spain, Panama, and Chile, is calling for the 2025 World Health Assembly to <u>adopt a resolution on rare diseases</u>. These are important developments towards health equity for a group of people with heterogeneous and too-often-neglected conditions. How hopeful should this population feel?

Undoubtedly, there are substantial challenges. More than 7000 different conditions are considered rare diseases: about 70% are genetic (such as cystic fibrosis and Duchenne muscular dystrophy), but the group also includes metabolic diseases, infectious diseases, autoimmune diseases, and rare cancers. Although a particular disease might affect only a few or even just one person, together 300 million people worldwide are estimated to live with a rare disease. However, because there is no single internationally recognised definition of rare disease, it is difficult to be precise about the exact burden.

And because individual diseases are uncommon, even the best health systems are not well adapted to care for patients. Diagnoses, if made at all, are often long delayed (on average it takes 4 years for a diagnosis of a known rare disease in Europe); specialised treatment and clinical expertise are lacking; and what drug treatments do exist are often very expensive, not funded by national health systems, and difficult to access. The cost to society is huge: one study estimated that the <u>economic cost</u> of 373 selected rare diseases in the USA was US\$2·2 trillion per year, compared with \$3·4 trillion per year for common diseases, such as diabetes, cancer, and cardiovascular diseases. Many patients face social stigma and discrimination and feel a sense of hopelessness and exclusion. These issues are likely to be even worse in low-income countries, where data are scarce.

These shared challenges and commonalities in experience (ie, having an often life-threatening or chronically debilitating disease, usually without cure, and coping with physical symptoms, side-effects of treatment, and performing daily activities) have prompted the grouping of these heterogeneous diseases together under the banner of rare diseases to help to drive advocacy and enable action. This approach has generated successes on many fronts. The Orphan Drug Act of 1983, which was advocated for by the National Organization for Rare Disorders in the USA (and later emulated in Europe), created incentives for pharmaceutical companies to develop drugs targeting rare diseases, leading to the approval of hundreds of treatments. Patient advocacy has also led to collaborations to improve care; for example, the European Reference Networks for rare diseases connect specialised centres with health-care providers, enabling access to pooled knowledge and resources, speeding up diagnosis, and helping patients to enrol in clinical trials. Many countries have implemented comprehensive genetic testing and newborn screening programmes, although most look only for disorders that can be treated effectively (only about 5% of rare diseases have approved treatments), and genetic testing is unavailable in many low-income and middle-income settings. Several countries now have national action plans for rare diseases, although many still do not.

A World Health Assembly resolution would be a culminating victory for patient advocacy. The hope is to make rare diseases a global health priority and provide a framework for countries to take action. A resolution could raise awareness, drive countries to produce national action plans, and set targets to bring much needed health equity to the forefront. A word of caution though: all too often such

documents, despite the best intentions, fail to make much difference for patients. Success depends on having a strong secretariat, robust accountability, and—perhaps most importantly—substantial funding and financing for implementation. Patient advocacy can achieve wonderful gains, but patient advocacy can only go so far. Those in a position to make demands a reality need to take heed and act accordingly.

### The Lancet Child & Adolescent Health

Oct 2024 Volume 8 Number 10 p707-792, e12-e15 <a href="https://www.thelancet.com/journals/lanchi/issue/current">https://www.thelancet.com/journals/lanchi/issue/current</a> [Reviewed earlier]

## **Lancet Digital Health**

Oct 2024 Volume 6 Number 10 e673-e771 <a href="https://www.thelancet.com/journals/landig/issue/current">https://www.thelancet.com/journals/landig/issue/current</a> [Reviewed earlier]

### **Lancet Global Health**

Oct 2024 Volume 12 Number 10 e1560-e1736 <a href="https://www.thelancet.com/journals/langlo/issue/current">https://www.thelancet.com/journals/langlo/issue/current</a> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Oct 2024 Volume 24 Number 10 p1059-1176, e602-e659 <a href="https://www.thelancet.com/journals/laninf/issue/current">https://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

## **Lancet Public Health**

Oct 2024 Volume 9 Number 10 e709-e830 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [Reviewed earlier]

## **Lancet Respiratory Medicine**

Oct 2024 Volume 12 Number 10 p743-836, e57-e64 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [Reviewed earlier]

#### **Maternal and Child Health Journal**

Volume 28, Issue 10 October 2024 <a href="https://link.springer.com/journal/10995/volumes-and-issues/28-10">https://link.springer.com/journal/10995/volumes-and-issues/28-10</a> [Reviewed earlier]

## **Medical Decision Making (MDM)**

Volume 44 Issue 7, October 2024 <a href="http://mdm.sagepub.com/content/current">http://mdm.sagepub.com/content/current</a>

# [Reviewed earlier]

## The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 3 Pages: 517-821 September 2024 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

## **Molecular Therapy**

Oct 02, 2024 Volume 32 Issue 10 p3195-3746 <a href="https://www.cell.com/molecular-therapy/current">https://www.cell.com/molecular-therapy/current</a> [Reviewed earlier]

#### **Nature**

Volume 634 Issue 8036, 31 October 2024 <a href="https://www.nature.com/nature/volumes/633/issues/8036">https://www.nature.com/nature/volumes/633/issues/8036</a> [New issue; No digest content identified]

# **Nature Biotechnology**

Volume 42 Issue 10, October 2024 <a href="https://www.nature.com/nbt/volumes/42/issues/10">https://www.nature.com/nbt/volumes/42/issues/10</a> [Reviewed earlier]

### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed02 Nov 2024) [No new digest content identified]

## **Nature Genetics**

Volume 56 Issue 10, October 2024 https://www.nature.com/ng/volumes/56/issues/10 Comment 09 Sept 2024

## **Defining and pursuing diversity in human genetic studies**

Calls for more diverse data in genetics studies typically fall short of offering further guidance. Here we summarize a policy framework from the Global Alliance for Genomics and Health designed to fill this gap. The framework prompts researchers to consider both what types of diversity are needed and why, and how aims can be achieved through choices made throughout the data life cycle. Maili C. Raven-Adams, Tina Hernandez-Boussard, Anna C. F. Lewis

### **Nature Human Behaviour**

Volume 8 Issue 10, October 2024 <a href="https://www.nature.com/nathumbehav/volumes/8/issues/10">https://www.nature.com/nathumbehav/volumes/8/issues/10</a> [Reviewed earlier]

#### **Nature Medicine**

Volume 30 Issue 10, October 2024 <a href="https://www.nature.com/nm/volumes/30/issues/10">https://www.nature.com/nm/volumes/30/issues/10</a> [Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 23 Issue 10, October 2024 https://www.nature.com/nrd/volumes/23/issues/10 [Reviewed earlier]

### **Nature Reviews Genetics**

Volume 25 Issue 10, October 2024 https://www.nature.com/nrg/volumes/25/issues/10 [Reviewed earlier]

# **Nature Reviews Immunology**

Volume 24 Issue 10, October 2024 <a href="https://www.nature.com/nri/volumes/24/issues/10">https://www.nature.com/nri/volumes/24/issues/10</a> [Reviewed earlier]

# **New England Journal of Medicine**

Volume 391 No. 17 October 31, 2024 <a href="https://www.nejm.org/toc/nejm/medical-journal">https://www.nejm.org/toc/nejm/medical-journal</a> [New issue; No digest content identified]

#### **NEJM Evidence**

Volume 3 No. 10 October 2024 https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

### njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 02 Nov 2024] [Reviewed earlier]

#### **Pediatrics**

Volume 154, Issue 4 October 2024 <a href="https://publications.aap.org/pediatrics/issue/154/4">https://publications.aap.org/pediatrics/issue/154/4</a> Articles
[Reviewed earlier]

#### **PharmacoEconomics**

Volume 42, Issue 10 October 2024 <a href="https://link.springer.com/journal/40273/volumes-and-issues/42-10">https://link.springer.com/journal/40273/volumes-and-issues/42-10</a> [Reviewed earlier]

## **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 02 Nov 2024) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 02 Nov 2024) [No new digest content identified]

### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 02 Nov 2024)

Improving the last mile delivery of vaccines through an informed push model: Experiences, opportunities and costs based on an implementation study in a rural district in Uganda

Pamela Bakkabulindi, Solomon T. Wafula, Anthony Ssebagereka, Rogers Sekibira, Aloysius Mutebi, Jimmy Ameny, Christabel Abewe, John Bosco Isunju

Research Article | published 28 Oct 2024 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0002647">https://doi.org/10.1371/journal.pgph.0002647</a>

### **PLoS Medicine**

https://journals.plos.org/plosmedicine/ (Accessed 02 Nov 2024) [No new digest content identified]

### **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 02 Nov 2024) [No new digest content identified]

## **PLoS One**

http://www.plosone.org/ [Accessed 02 Nov 2024]

**Examining HPV vaccination behavior among young adults: Insights from applying the Health Belief Model** 

Oluwafemifola Oyedeji, Kristina W. Kintziger, Cary M. Springer, Samantha Ehrlich, Jill Maples, Justin Gatwood, Cristina S. Barroso

Research Article | published 01 Nov 2024 PLOS ONE https://doi.org/10.1371/journal.pone.0312700

# <u>Identifying the zero-dose and under-immunized children in Bangladesh: Approaches and experiences</u>

Zerin Jannat, Hemel Das, Md. Wazed Ali, Nurul Alam, Mahbub E. Elahi Khan Chowdhury, Bidhan Krishna Sarker, Md. Mahbubur Rahman, Shehrin Shaila Mahmood, Md. Musfikur Rahman, Christopher Morgan, Elizabeth Oliveras, Gustavo Caetano Correa, Heidi W. Reynolds, Tasnuva Wahed, Md. Jasim Uddin

Research Article | published 28 Oct 2024 PLOS ONE https://doi.org/10.1371/journal.pone.0312171

# The TB vaccine clinical trial centre directory: An inventory of clinical trial centres in Sub-Saharan Africa

Puck T. Pelzer, Marit Holleman, Michelle E. H. Helinski, Ana Lucia Weinberg, Joeri Buis, Pauline Beattie, Thomas Nyirenda, Job van Rest, Gerald Voss Research Article | published 28 Oct 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0292981

## **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 02 Nov 2024] [No new digest content identified]

## PNAS - Proceedings of the National Academy of Sciences of the United States

October 29, 2024 vol. 121 no. 44 https://www.pnas.org/toc/pnas/121/44 Research Article October 21, 2024

# **Ecological change increases malaria risk in the Brazilian Amazon**

Ecological change in the Brazilian Amazon is closely linked to human mobility and health. Mining, agriculture, logging, and other activities alter highly diverse ecological and demographic contexts and subsequent exposure to diseases such as malaria. ...

Nicholas J. Arisco, et al.

## **PNAS Nexus**

Volume 3, Issue 10, October 2024 https://academic.oup.com/pnasnexus/issue/3/10 Public Health and Epidemiology

## <u>Influenza vaccine allocation in tropical settings under constrained resources</u>

Joseph L Servadio and others

PNAS Nexus, Volume 3, Issue 10, October 2024, pgae379,

https://doi.org/10.1093/pnasnexus/pgae379

# **Prehospital & Disaster Medicine**

Volume 39 - Issue 3 - June 2024 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 187 October 2024

https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C [Reviewed earlier]

# **Proceedings of the Royal Society B**

October 2024 Volume 291 Issue 2032 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [Reviewed earlier]

#### **Public Health**

Volume 235 Pages 1-218 (October 2024) <a href="https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C">https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C</a> [Reviewed earlier]

#### **Public Health Ethics**

Volume 17, Issue 1-2, April/July 2024 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

#### **Public Health Genomics**

2024, Vol. 27, No. 1 https://karger.com/phg/issue/27/1 [Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 5, September/October 2024 <a href="https://journals.sagepub.com/toc/phrg/139/5">https://journals.sagepub.com/toc/phrg/139/5</a> [Reviewed earlier]

## **Qualitative Health Research**

Volume 34 Issue 12, October 2024 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [New issue; No digest content identified]

#### **Research Ethics**

Volume 20 Issue 4, October 2024 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

## **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 02 Nov 2024] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 30 Oct 2024

Challenges to the digital inclusion of women in a vulnerable area in Colombia

Original research | Spanish |

30 Oct 2024

The private market for antimicrobials: an exploration of two selected mining and frontier areas of Guyana

Special report | English |

# **Risk Analysis**

Volume 44, Issue 10 Pages: 2313-2515 October 2024 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

## **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 02 Nov 2024] [No new digest content identified]

#### **Science**

Volume 386| Issue 6721| 1 Nov 2024 https://www.science.org/toc/science/current Editorial

**Gender parity in African science** 

BY Kwabena Boahen Asare, Fatima Cody Stanford 31 Oct 2024

### **Science and Engineering Ethics**

Volume 30, Issue 5 October 2024 https://link.springer.com/journal/11948/volumes -and-issues/30-5 [Reviewed earlier]

## **Science Translational Medicine**

Volume 16| Issue 771| 30 Oct 2024 https://www.science.org/toc/stm/current [New issue; No digest content identified]

## **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 02 Nov 2024] [No new digest content identified]

#### **Social Science & Medicine**

Volume 358 October 2024

https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C

[Reviewed earlier]

# **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 02 Nov 2024] [No new digest content identified]

#### **Theoretical Medicine and Bioethics**

Volume 45, Issue 5 October 2024 https://link.springer.com/journal/11017/volumes-and-issues/45-5 [Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 61 September–October 2024 <a href="https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C">https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C</a> [Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 29, Issue 10 Pages: i-iv, 849-921 October 2024 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### **Vaccine**

Volume 42, Issue 25 14 November 2024 <a href="https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25">https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25</a> [Reviewed earlier]

#### **Vaccines**

https://www.mdpi.com/journal/vaccines

[Accessed 02 Nov 2024]

Open Access Systematic Review

<u>Systematic Review on Influenza Burden in Emerging Markets in 2018–2023—An Evidence Update to Guide Influenza Vaccination Recommendations</u>

by Moe H. Kyaw, Sophie Bozhi Chen, Shishi Wu, Chee Yoong Foo, Verna Welch, Constantina Boikos and Oladayo Jagun

Vaccines 2024, 12(11), 1251; https://doi.org/10.3390/vaccines12111251 (registering DOI) - 2 Nov 2024

**Abstract** 

Background: Influenza is a contagious respiratory illness responsible for seasonal epidemics and with potential to cause pandemics. The decline in influenza-related studies published since 2018 resulted in data gaps, particularly in emerging markets. Methods: This systematic review searched for studies in six databases [...

Open Access Article

# The Costs and Cost-Effectiveness of a Two-Dose Oral Cholera Vaccination Campaign: A Case Study in a Refugee Camp Setting in Thailand

by Aaron S. Wallace, Kashmira Date, Sarah W. Pallas, Nuttapong Wongjindanon, Christina R. Phares and Taiwo Abimbola

Vaccines 2024, 12(11), 1235; <a href="https://doi.org/10.3390/vaccines12111235">https://doi.org/10.3390/vaccines12111235</a> - 30 Oct 2024 Abstract

Oral cholera vaccination (OCV) campaigns are increasingly used to prevent cholera outbreaks; however, little is known about their cost-effectiveness in refugee camps. We conducted a cost-effectiveness analysis of a pre-emptive OCV campaign in the Maela refugee camp in Thailand, where outbreaks occurred with [...]

Open Access Editorial

# Special Issue: "Vaccination and Global Health"

by Shaodi Ma, Qian Bi, Li Liu, Roshan Thapa, Wenle Li, Baocheng Liu, Chuanhui Xu and Chenyu Sun Vaccines 2024, 12(11), 1223; <a href="https://doi.org/10.3390/vaccines12111223">https://doi.org/10.3390/vaccines12111223</a> - 28 Oct 2024

\*\*Abstract\*

This Special Issue, titled 'Vaccination and Global Health,' compiles 11 broad-ranging papers, each exploring critical facets of vaccination, public health, and global healthcare systems [...]

Overview of Published Papers

The articles featured in this Special Issue cover a broad spectrum of topics, ranging from the development of novel vaccine technologies to the evaluation of vaccine efficacy across diverse populations. Several papers focus on the public health implications of vaccination programs, offering valuable insights into vaccine coverage, hesitancy, and the efficacy of global immunization efforts  $[\underline{3},\underline{4},\underline{5}]$ . In one of the studies, Contoli et al. explores the willingness of foreign residents in Italy to be vaccinated, revealing the challenges faced by immigrant populations in terms of vaccine uptake. Their findings suggest the need for targeted communication strategies to increase vaccination rates in different communities  $[\underline{2}]$ . Other articles examine the barriers to vaccine access in resource-limited settings and propose strategies to enhance global vaccine distribution  $[\underline{1},\underline{6}]$ . Moreover, researchers also provide evidence for delivering vaccines as part of a humanitarian response by conducting a systematic review, which has contributed to the mapping of the normative landscape of vaccination guidance for vaccine-preventable diseases in crisis-affected settings  $[\underline{10}]$ .

A notable contribution is a study evaluating the implementation of COVID-19 vaccination programs in low- and middle-income countries [8]. The authors provide compelling evidence demonstrating the success of localized strategies tailored to specific regions. Another significant paper explores vaccine hesitancy by examining the socio-cultural factors that shaped public attitudes toward vaccination during the COVID-19 pandemic [4]. In addition, Kunieda et al. investigated the factors influencing measles vaccination rates in Niger [6], and recommended an increased focus on equity-based individual factors, including personal motivation, prompts and ability to access vaccination services. These studies provide valuable information and in-depth insights for enhancing vaccine acceptance globally, particularly through targeted educational campaigns and community engagement strategies [4,6].

#### Value in Health

October 2024 Volume 27 Issue 10 p1311-1468 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

# **World Development**

Volume 182 October 2024

https://www.sciencedirect.com/journal/world-development/vol/182/suppl/C [Reviewed earlier]

::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: <u>Journal Watch</u>

:: Pre-Print Servers

::::::

## **Pre-Print Servers**

#### arxiv

https://arxiv.org/

[Accessed 02 Nov 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology;

General Economics]

arXiv:2410.21344 (cross-list from physics.soc-ph) [pdf, other]

<u>Estimating the epidemic threshold under individual vaccination behaviour and adaptive</u> <u>social connections: A game-theoretic complex network model</u>

Viney Kumar, Chris T Bauch, Samit Bhattacharyya

Information dissemination intricately intertwines with the dynamics of infectious diseases in the contemporary interconnected world. Recognizing the critical role of public awareness, individual vaccination choices appear to be an essential factor in collective efforts against emerging health threats. This study aims to characterize disease transmission dynamics under evolving social connections, information sharing, and individual vaccination decisions. To address this important problem, we present an integrated behaviour-prevalence model on an adaptive multiplex network...

#### **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 02 Nov 2024] [No new digest content identified]

## medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 02 Nov 2024] [Filter: All articles]

<u>Factors Associated with Measles Vaccine Immunogenicity in Children at University Teaching Hospitals, Lusaka, Zambia</u>

Priscilla Nkonde Gardner, Cephas Sialubanje Fwemba

medRxiv 2024.10.30.24316424; doi: https://doi.org/10.1101/2024.10.30.24316424

<u>Estimating historical impacts of vaccination against influenza B/Yamagata in the United States to inform possible risks of re-emergence in the absence of vaccination</u>

Sinead E Morris, Sarabeth M Mathis, Jessie R Chung, Brendan Flannery, Alissa O'Halloran, Catherine H Bozio, Peng-Jun Lu, Tammy A Santibanez, Peter Daly, Angiezel Merced-Morales, Krista Kniss, Alicia Budd, Lisa A Grohskopf, Carrie Reed, Matthew B, Jimmy Hangoma, Roma Chilengi, Muzala Kapina, Musole Chipoya, Kelvin Mwangilwa, Lillian Lambaku Mwenechanya, Rodgers Chilyabanyama, Mpanga Kasonde, Soo Young, Davie Simwaba, Isaac iggerstaff, A Danielle Iuliano medRxiv 2024.10.30.24316093; doi: https://doi.org/10.1101/2024.10.30.24316093

<u>Assessing Dengue Virus Importation Risks in Africa: A Climate and Travel-Based Model</u> Jenicca Poongavanan, José Lourenço, Joseph L.-H. Tsui, Vittoria Colizza, Yajna Ramphal, Cheryl Baxter,

Moritz U.G. Kraemer, Marcel Dunaiski, Tulio de Oliveira, Houriiyah Tegally, Musa medRxiv 2024.05.07.24306997; doi: https://doi.org/10.1101/2024.05.07.24306997 Revision

# Knowledge, Attitude, and Practices Regarding Dengue Infection: A Community-Based Study in Rural Cox's Bazar

Ely Prue, Al Asmaul Husna, Shazia Rokony, Aung Sain Thowai, Shahra Tanjim Moulee, Afsana Jahan, Aysha Khatun, Moloy Sarkar, Saima Bibi, Tahsin Tasneem Tabassum, Mohammad Nurunnabi medRxiv 2024.10.27.24316216; doi: https://doi.org/10.1101/2024.10.27.24316216

A decade of dengue disease burden in Africa (2013-2023): a systematic review

Gaspary O. Mwanyika, Monika Moir, Abdualmoniem O. Musa, Jenicca Poongavanan, Graeme Dor, Eduan Wilkinson, Cheryl Baxter, Tulio de Oliveira, Houriiyah Tegally medRxiv 2024.10.22.24315827; doi: https://doi.org/10.1101/2024.10.22.24315827

# A nationwide joint spatial modelling of simultaneous epidemics of dengue, chikungunya, and Zika in Colombia

Laís Picinini Freitas, Mabel Carabali, Alexandra M. Schmidt, Jorge Emilio Salazar Flórez, Brayan Ávila Monsalve, César García-Balaguera, Berta N. Restrepo, Gloria I. Jaramillo-Ramirez, Kate Zinszer medRxiv 2024.10.25.24316124; doi: https://doi.org/10.1101/2024.10.25.24316124

# **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre[No new digest content identified]

### **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles [Accessed 02 Nov 2024] Review Open Access

The Ubuntu Way: Ensuring Ethical AI Integration in Health Research

[version 1; peer review: awaiting peer review] Brenda Odero, David Nderitu, Gabrielle Samuel Abstract

The integration of artificial intelligence (AI) in health research has grown rapidly, particularly in African nations, which have also been developing data protection laws and AI strategies. However, the ethical frameworks governing AI use in health research are often based on Western philosophies, focusing on individualism, and may not fully address the unique challenges and cultural contexts of African communities. This paper advocates for the incorporation of African philosophies, specifically Ubuntu, into AI health research ethics frameworks to better align with African values and contexts.

This study explores the concept of Ubuntu, a philosophy that emphasises communalism, interconnectedness, and collective well-being, and its application to AI health research ethics. By

analysing existing global AI ethics frameworks and contrasting them with the Ubuntu philosophy, a new ethics framework is proposed that integrates these perspectives. The framework is designed to address ethical challenges at individual, community, national, and environmental levels, with a particular focus on the African context.

The proposed framework highlights four key principles derived from Ubuntu: communalism and openness, harmony and support, research prioritisation and community empowerment, and community-oriented decision-making. These principles are aligned with global ethical standards such as justice, beneficence, transparency, and accountability but are adapted to reflect the communal and relational values inherent in Ubuntu. The framework aims to ensure that AI-driven health research benefits communities equitably, respects local contexts and promotes long-term sustainability...

\* \* \* \*

# Think Tanks

**Brookings** [to 02 Nov 2024] http://www.brookings.edu/ Research No new digest content identified.

## **Center for Global Development** [to 02 Nov 2024]

https://www.cgd ev.org/ All Research No new digest content identified.

## **Chatham House** [to 02 Nov 2024]

https://www.chathamhouse.org/ Selected Analysis, Comment, Events Event recording

## Watch: Is the world ready for the next pandemic?

In a joint event with The Elders, Helen Clark, Ban Ki-moon and other experts discuss the policies needed to prevent the next health catastrophe.

29 October 2024 1 hour watch

#### **Council on Foreign Relations** [to 02 Nov 2024]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 02 Nov 2024]
<a href="https://www.csis.org/">https://www.csis.org/</a>
Reports [Selected]
No new digest content identified.

**Kaiser Family Foundation** [to 02 Nov 2024] https://www.kff.org/search/?post\_type=press-release

Newsroom No new digest content identified.

# McKinsey Global Institute [to 02 Nov 2024]

https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

# **ODI [Overseas Development Institute]** [to 02 Nov 2024]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

## **Pew Research Center** [to 02 Nov 2024]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 02 Nov 2024] https://www.rand.org/pubs.html Published Research [Selected] No new digest content identified.

Urban Institute [to 02 Nov 2024]
<a href="https://www.urban.org/publications">https://www.urban.org/publications</a>
New Research Publications - Selected

### **World Economic Forum** [to 02 Nov 2024]

https://agenda.weforum.org/press/ Media [Selected] No new digest content identified.

::::::

## **Public Consultations/Call for Inputs/Call for Papers**

Request for Information (RFI): To Inform the Development of the 2026-2030 National HIV/AIDS Strategy and the National Strategic Plans for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis

US Health and Human Services Department - 10/07/2024 **Comment period ends December 6, 2024.** 

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.